ArticleProceedings of the National Academy of Sciences of the United States of America2023
SMARCB1 regulates the hypoxic stress response in sickle cell trait.
Open access · greenAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 24 citations in OpenAlex.
- Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence.Nature communications · 2025Trial
- Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank.Urologic oncology · 2026Article
- Renal Medullary Carcinoma: Utility of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Review
- Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profiling.Cell reports. Medicine · 2025Article
- Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell Carcinoma.Molecular cancer therapeutics · 2025Article
- Molecular and therapeutic landscape of non-clear cell renal carcinoma.Nature reviews. Urology · 2025Review
- Vigorous physical activity as a potential environmental risk factor in renal medullary carcinoma.Urologic oncology · 2025Article
- Article
- CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Differentiating between renal medullary and clear cell renal carcinoma with a machine learning radiomics approach.The oncologist · 2025Article
- A novel case of glial transdifferentiation in renal medullary carcinoma brain metastasis.Acta neuropathologica communications · 2025Article
- Case Report: Successful delivery following chemotherapy in a pregnant patient with metastatic SMARCB1-deficient renal medullary carcinoma.Frontiers in oncology · 2025Article
- Recent progress in non-clear cell renal cell carcinoma: biology and therapeutic strategies.Therapeutic advances in medical oncology · 2025Review
- Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2024Review
- The 5th Kidney Cancer Research Summit: Research Accelerating Cures for Renal Cell Carcinoma in 2023.The oncologist · 2024Article
- Ferroptosis as an emerging target in sickle cell disease.Current research in toxicology · 2024Article
- Obesity and renal cell carcinoma: Biological mechanisms and perspectives.Seminars in cancer biology · 2023Review
- A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 6 institutions in 2 countries.
Melinda SoeungDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.ORCID 0000-0002-6902-898X
Luigi PerelliDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.
Ziheng ChenDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.
Eleonora DondossolaDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.ORCID 0000-0001-6916-5418
I-Lin HoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.ORCID 0000-0002-8914-710X
Federica CarboneNerviano Medical Sciences, Milan 20014, Italy.ORCID 0000-0001-8697-0304
Li ZhangDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.
Hania KhanDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.
Courtney N LeDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.ORCID 0000-0003-4456-1478
Cihui ZhuDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.
Michael D PeoplesTranslational Research to Advance Therapeutics and Innovation in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.ORCID 0000-0001-5233-2603
Ningping FengTranslational Research to Advance Therapeutics and Innovation in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.
Shan JiangTranslational Research to Advance Therapeutics and Innovation in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.
Niki Millward ZachariasDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.
Rosalba MinelliTranslational Research to Advance Therapeutics and Innovation in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.
Daniel D ShapiroDivision of Urology, William S. Middleton Memorial VA Hospital, Madison, WI 53705.
Angela K DeemDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.
Sisi GaoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.
Emily H ChengDepartment of Pathology, Memorial Sloan Kettering Cancer Institute, New York City, NY 10065.
Donatella LucchettiDepartment of Translational Medicine and Surgery-Faculty of Medicine and Surgery, Catholic University of the Sacred Heart, Rome 00168, Italy.
Cheryl L WalkerCenter for Precision Environmental Health, Baylor College of Medicine, Houston, TX 77030.
Alessandro CarugoTranslational Research to Advance Therapeutics and Innovation in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.ORCID 0000-0001-5182-3320
Virginia GiulianiTranslational Research to Advance Therapeutics and Innovation in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.
Timothy P HeffernanTranslational Research to Advance Therapeutics and Innovation in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.
Andrea VialeDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.ORCID 0000-0003-4328-1044
Nizar M TannirDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.ORCID 0000-0001-5559-8060
Giulio F DraettaDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.ORCID 0000-0001-5225-9610
Pavlos MsaouelDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.ORCID 0000-0001-6505-8308
Giannicola GenoveseDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USMemorial Sloan Kettering Cancer Center · USNerviano Medical Sciences · ITUniversità Cattolica del Sacro Cuore · ITWilliam S. Middleton Memorial Veterans Hospital · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MTargeting Tumor Microenvironment-Induced Therapy Resistance in Prostate Cancer Bone MetastasisP50CA140388 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THOMPSON, TIMOTHY CHARLES · 2009 to 2022
$23.4MA New Target for Chromatin Remodeler Defects in CancerR35CA231993 · NCI · BAYLOR COLLEGE OF MEDICINE · PI WALKER, CHERYL L. · 2018 to 2024
$6.2MGenetic Loss-of-Function Studies of SETD2 in Kidney TumorigenesisR01CA223231 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHENG, EMILY H · 2018 to 2022
$2.7MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA140388NCI NIH HHS R01 CA223231
Abstract
Renal medullary carcinoma (RMC) is an aggressive kidney cancer that almost exclusively develops in individuals with sickle cell trait (SCT) and is always characterized by loss of the tumor suppressor
Indexed as
Carcinoma, Renal CellKidney NeoplasmsSickle Cell TraitAnimalsHumansHypoxiaKidneyMiceSMARCB1 ProteinSMARCB1 Proteinhypoxiarenal medullary carcinomasickle cell traitSMARCB1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.